MedTrace Logo

The Efficacy and Tolerability of Duloxetine for the Treatment of Panic Disorder

NCT00438971 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2016-04-27

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether duloxetine is effective in the treatment of panic disorder.

Conditions

  • Panic Disorder

Interventions

DRUG

Duloxetine

Treatment will be initiated at 30mg/day in the first week (week 0), and then increased to 60mg/day at week 1, with the option to increase to 90mg at week 4, and 120mg at week 6.

Sponsors & Collaborators

Principal Investigators

  • Mark H Pollack, M.D. · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-08-31
Primary Completion
2009-01-31
Completion
2009-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00438971 on ClinicalTrials.gov